SCHOTT Pharma's Q3 2025 Highlights and FY 2025 Outlook

SCHOTT Pharma reports a revenue increase of 3% year-over-year (yoy) in Q3 2025, reaching EUR 256 million at constant currencies. The EBITDA rose by 11% yoy to EUR 83 million, yielding a quarterly margin of 32.4%. The growth was mainly driven by a robust demand for High Value Solutions (HVS), contributing to 60% of revenues. The company now projects an organic revenue growth of around 6.0% for the fiscal year 2025, aligning with the lower end of initial expectations.

The anticipated EBITDA margin for the full year is revised upwards to approximately 28.0%, surpassing the FY 2024 level of 26.9%. This adjustment reflects the ongoing demand for HVS, especially sterile cartridges and specialty vials, along with operational efficiencies. SCHOTT Pharma plans to release its comprehensive Q3/9M 2025 financial results on August 12, 2025.